Baillie Gifford & CO Sarepta Therapeutics, Inc. Transaction History

Baillie Gifford & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$117.53 - $155.99 $3,760 - $4,991	32 Added 16.08%	231 $31,000
Q2 2022 Aug 08, 2022	BUY	$62.69 - $88.44 $1,379 - $1,945	22 Added 12.43%	199 $15,000
Q3 2021 Oct 19, 2021	SELL	$65.97 - $92.48 $1,847 - $2,589	-28 Reduced 13.66%	177 $16,000
Q1 2021 May 06, 2021	BUY	$72.25 - $168.95 $1,950 - $4,561	27 Added 15.17%	205 $15,000
Q4 2020 Feb 10, 2021	BUY	$125.56 - $178.74 $22,349 - $31,815	178 New	178 $30,000

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.